DISODIUM 4-((TERT-BUTYLIMINO)METHYL)BENZENE-1,3-DISULFONATE N-OXIDE
Brain Glioblastoma
Oblato, Inc.Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
16 Active assets in the Brain Glioblastoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tvi-Brain-1 TVAX Biomedical | Phase 2/3 | B |
Ruxolitinib Baptist Health South Florida | Phase 2 | CCC |
Belinostat Emory University | Phase 2 | CCC |
Avelumab Clinique Neuro-Outaouais | Phase 2 | CCC |
Pembrolizumab University Hospital, Geneva | Phase 1/2 | CCC |
View all 22 →
Same molecule, other indications
DISODIUM 4-((TERT-BUTYLIMINO)METHYL)BENZENE-1,3-DISULFONATE N-OXIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →